Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression

被引：3
作者：
Kim, Hyun Jung [1 ]
Kim, Aeree [2 ]
Ahn, Hyeongsik [1 ]
Ahn, Il Min [1 ,3 ]
Choi, Jinhyuk [2 ]
Chang, Hyeyoon [2 ]
机构：
[1] Korea Univ, Coll Med, Dept Prevent Med, Seoul 152703, South Korea
[2] Korea Univ, Coll Med, Dept Pathol, Guro Hosp, Seoul 152703, South Korea
[3] Brown Univ, Dept Literary Arts, Providence, RI 02912 USA
来源：
APMIS | 2015年 / 123卷 / 05期
关键词：
ErbB3; breast cancer; prognosis; meta-analysis; GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; CELLS; PROTEIN; ACTIVATION; GENE; HETERODIMERIZATION; TRANSFORMATION; RESISTANCE; INHIBITORS;
D O I：
10.1111/apm.12371
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Prognostic value of ErbB3 in human breast cancer is still controversial. However, the roles of ErbB3 receptors in drug resistance are recently emerging. The objective of this study was to evaluate the relationship between ErbB3 expression and survival of breast cancer via meta-analysis. A systematic literature search was conducted and 32 potentially relevant studies were included in the meta-analysis. Outcomes presented in searched literatures can be classified as disease free survival (DFS), overall survival (OS), and progress free survival (PFS) values. Meta-analysis was performed for each group. Results showed no statistically significant difference in survival. The overall hazard ratio of PFS, DFS, and OS of ErbB3 expression was 1.40 [95% confidence interval/CI (0.51, 3.83)], 1.07 [95% CI (0.82, 1.40)], and 1.15 [95% CI (0.91, 1.44)], respectively. Subgroup analysis according to ErbB2 receptor status, ErbB3 assessment methods (immunohistochemistry/IHC vs non-IHC), and analysis type (multivariate and univariate analysis) were performed. No significant association was found. Using various assessment methods and patient populations, our results revealed that there was no significant correlation between ErbB3 expression and breast cancer survival. Further studies on heterodimers of ErbB3 and other molecular markers involved in ErbB3 related pathway are merited.
引用
收藏
页码：383 / 393
页数：11
相关论文
共 35 条
[1]  
ALIMANDI M, 1995, ONCOGENE, V10, P1813
[2]  
[Anonymous], CHEMOTHER RES PRACT
[3]  
[Anonymous], COCHRANE HDB SYSTEMA
[4]   The promise of anti-ErbB3 monoclonals as new cancer therapeutics [J].
Aurisicchio, Luigi ;
Marra, Emanuele ;
Roscilli, Giuseppe ;
Mancini, Rita ;
Ciliberto, Gennaro .
ONCOTARGET, 2012, 3 (08) :744-758
[5]   Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors [J].
Aurisicchio, Luigi ;
Marra, Emanuele ;
Luberto, Laura ;
Carlomosti, Fabrizio ;
De Vitis, Claudia ;
Noto, Alessia ;
Gunes, Zeynep ;
Roscilli, Giuseppe ;
Mesiti, Giuseppe ;
Mancini, Rita ;
Alimandi, Maurizio ;
Ciliberto, Gennaro .
JOURNAL OF CELLULAR PHYSIOLOGY, 2012, 227 (10) :3381-3388
[6]   THE NEU ONCOGENE ENCODES AN EPIDERMAL GROWTH-FACTOR RECEPTOR-RELATED PROTEIN [J].
BARGMANN, CI ;
HUNG, MC ;
WEINBERG, RA .
NATURE, 1986, 319 (6050) :226-230
[7]   Emerging roles of pseudokinases [J].
Boudeau, Jerome ;
Miranda-Saavedra, Diego ;
Barton, Geoffrey J. ;
Alessi, Dario R. .
TRENDS IN CELL BIOLOGY, 2006, 16 (09) :443-452
[8]   Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase [J].
Chang, HW ;
Aoki, M ;
Fruman, D ;
Auger, KR ;
Bellacosa, A ;
Tsichlis, PN ;
Cantley, LC ;
Roberts, TM ;
Vogt, PK .
SCIENCE, 1997, 276 (5320) :1848-1850
[9]   Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation [J].
Contessa, JN ;
Abell, A ;
Mikkelsen, RB ;
Valerie, K ;
Schmidt-Ullrich, R .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 95 (01) :17-27
[10]   TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].
COUSSENS, L ;
YANGFENG, TL ;
LIAO, YC ;
CHEN, E ;
GRAY, A ;
MCGRATH, J ;
SEEBURG, PH ;
LIBERMANN, TA ;
SCHLESSINGER, J ;
FRANCKE, U ;
LEVINSON, A ;
ULLRICH, A .
SCIENCE, 1985, 230 (4730) :1132-1139
1234